共 50 条
- [1] Vedolizumab is superior to anti-tumor necrosis factor agents as a first-line biological agent but not as a second-line biological agent in moderate to severe ulcerative colitisJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 136 - 136Pudipeddi, A.Ko, Y.Paramsothy, S.Leong, R.
- [2] Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2018, 32-33 : 17 - 25Pouillon, LievenVan Stappen, JohanBossuyt, PeterDanese, SilvioPeyrin-Biroulet, Laurent
- [3] IMMUNOMODULATOR CO-THERAPY IMPROVES MEDICATION PERSISTENCE OF FIRST-LINE ANTI-TUMOR NECROSIS FACTOR AGENTS AND FIRST-LINE VEDOLIZUMAB, BUT NOT SECOND-LINE THERAPY, IN MODERATE-TO-SEVERE ULCERATIVE COLITISGASTROENTEROLOGY, 2021, 160 (06) : S343 - S344Pudipeddi, AvivKo, YannaParamsothy, SudarshanLeong, Rupert W.
- [4] Ulcerative Colitis Therapy: Vedolizumab as a First-line Biologic Agent?ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (03): : 274 - 276Metzger, Leandra
- [5] Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyTHERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15Pudipeddi, AvivKo, YannaParamsothy, SudarshanLeong, Rupert W.
- [6] Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitisBMJ OPEN GASTROENTEROLOGY, 2016, 3 (01):Yokomizo, LaurenLimketkai, BerkeleyPark, K. T.
- [7] Concomitant immunomodulator use improves medication persistence of anti-tumor necrosis factor agents and vedolizumab in moderate to severe ulcerative colitisJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 137 - 138Pudipeddi, A.Ko, Y.Paramsothy, S.Leong, R.
- [8] Use and impact of immunomodulator cotherapy with first-line and second-line antitumor necrosis factor agents in Crohn's disease and ulcerative colitisJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 122 - 123Pudipeddi, A.Paramsothy, S.Leong, R.
- [9] UTILISATION AND IMPACT OF IMMUNOMODULATOR CO-THERAPY WITH FIRST-LINE AND SECOND-LINE ANTI-TUMOUR NECROSIS FACTOR AGENTS IN CROHNS DISEASE AND ULCERATIVE COLITISGASTROENTEROLOGY, 2022, 162 (07) : S609 - S609Pudipeddi, AvivParamsothy, SudarshanLeong, Rupert
- [10] FIRST-LINE AND SECOND-LINE BIOLOGIC AGENTS AND SMALL MOLECULES IN THE MANAGEMENT OF MODERATE-SEVERE ULCERATIVE COLITIS: A GRADE-BASED APPROACHGASTROENTEROLOGY, 2017, 152 (05) : S592 - S593Singh, SiddharthFumery, MathurinDulai, ParambirMurad, MohammadSandborn, William J.